Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI145097)
ONL Therapeutics (Sponsored Research Grant)
NEI (EY021543, P30EY003790)
Text and Data Mining valid from 2019-09-30
Received: 14 May 2019
Accepted: 29 August 2019
First Online: 30 September 2019
Ethics approval and consent to participate
: All animal experiments were approved by the Institutional Animal Care and Use Committee at Schepens Eye Research Institute and were performed under the guidelines of the Association of Research in Vision and Ophthalmology (Rockville, MD).
: Not applicable
: AJK is employed by ONL Therapeutics. DNZ is a co-founder, equity holder, and consultant to ONL Therapeutics. Dr. Zacks is also a co-inventor on ONL’s patent applications, as well as on patents and applications licensed by ONL Therapeutics from the University of Michigan and Massachusetts Eye and Ear that are based on the development and use of novel Fas inhibitors. MGK received a sponsored research grant from ONL Therapeutics. AK, AJK, DNZ, MGK are co-inventors on two patent applications submitted by ONL Therapeutics based in part on the results reported herein. MGK and AMR are co-inventors on a patent application on soluble Fas ligand as a neuroprotective therapeutic that has been licensed by ONL Therapeutics from University of Medical School Worcester and Massachusetts Eye and Ear.